Dapagliflozin for kids with genetic kidney disease and protein in urine
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if dapagliflozin, a medication that lowers blood sugar and protects the kidneys, can reduce protein in the urine of children with inherited kidney disease. It may help preserve kidney function when added to standard blood pressure medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic kidney disease (tested by genetic testing or diagnosed by a doctor).
- Your urine must have more than a small amount of protein (over 0.2 grams in 24 hours or a specific ratio).
- Kidney function must be at least 60% of normal (measured by a blood test).
- You must be on a stable dose of a certain blood pressure medicine (ACE inhibitor or ARB) for at least 4 weeks.
- You cannot have used steroids or other immune-suppressing medicines, or another drug called SGLT2 inhibitor, in the last 4 weeks.
- You cannot have diabetes, a current urinary tract infection, very low blood pressure, or a history of organ transplant or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called LC-Z300-01 to see if it can reduce protein in the urine of people with diabetic kidney disease. It aims to protect kidney function and slow down kidney damage.
This trial tests dapagliflozin, a daily medicine, to slow kidney problems in people with early-stage chronic kidney disease caused by Alport syndrome. It may help protect kidney function and reduce worsening over time.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
Hear when a new Pediatric Hereditary Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.